DEVELOPMENT AND VALIDATION OF UPLC METHOD FOR THE SIMULTANEOUS DETERMINATION OF ATORVASTATIN AND EZETIMIBE IN PHARMACEUTICAL FORMULATION by Sharma Amit Kumar & Dharamsi Abhay
Sharma Amit Kumar et al. IRJP 2012, 3 (3) 
Page 200 
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY 
www.irjponline.com  ISSN 2230 – 8407 
Research Article 
 
 
DEVELOPMENT AND VALIDATION OF UPLC METHOD FOR THE SIMULTANEOUS 
DETERMINATION OF ATORVASTATIN AND EZETIMIBE IN PHARMACEUTICAL 
FORMULATION 
Sharma Amit Kumar*, Dharamsi Abhay
 
Department of Pharmaceutical Analysis, Tirumala College of Pharmacy,Tirumala Nagar, Bardipur(V), Dichpally(M), 
Nizamabad, India 
 
Article Received on: 05/01/12 Revised on: 20/02/12 Approved for publication: 20/03/12 
 
*E-mail: rohitrx@gmail.com 
 
ABSTRACT 
A simple, rapid and accurate UPLC method was developed and validated for estimation of atorvastatin and ezetimibe in combined dosage forms. With the 
objective of reducing analysis time and maintaining good efficiency in the area of fast chromatographic separations the UPLC has proven to be one of the most 
promising developments in the area of fast chromatographic separations. In this work a isocratic reverse phase chromatographic method was developed using 
UPLC for the estimation of atorvastatin and ezetimibe in pharmaceutical formulations. The chromatographic separation of atorvastatin and ezetimibe  was 
achieved as waters acquity BEH C18,50*2.1mm,1.7um column within a short runtime of 8min by using pioglitazone as IS. The method was validated according 
to the regulatory guidelines with respect to precision, accuracy and linearity. 
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INTRODUCTION 
Atorvastatin  (Fig-I)  is  chemically[R-(R*,  R*0]-2-(4-
Fluorophenyl)-b, g-dehydroxy-5-(1-mehtylethyl)-3-phenyl-4-
[9phenylamino)-carbonyl]-1H-pyrrole-1-heptanoic  acid.  It 
competitively  inhibits  (HMG-CoA)  reductase,  the  enzyme 
that catalyzes the conversion of HMG-CoA to mevalonate, an 
early  rate  limiting  step  in  cholesterol  biosynthesis,  HMG-
CoA  reductase  inhibitors  increase  HDL  cholesterol  and 
decrease  LDL  cholesterol  (LDL-C),  VLDL  cholesterol  and 
plasma  triglycerides.Ezetimibe  (Fig-I)  is  chemically  1,-(4-
fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxy-propyl]-4-(4-
hydroxy phenyl) - azetidin-2-one. Ezetimibe localizes at the 
brush  border  of  the  small  intestine  where  it  inhibits  the 
absorption of cholesterol, decreasing the delivery of intestinal 
cholesterol to the liver
1-7. 
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Figure1. The structure of Atorvastatin and Ezetimibe 
 
MATERIALS AND METHODS 
Apparatus 
UPLC  waters acquity system equipped with binary solvent 
delivery  pump  an  auto  sampler and tunable  PDA  detector, 
water acquity BEH 50*2.1mm, 1.7um, C18 column. 
Materials: Atorvastatin standards were obtained from Zydus 
Medica  laboratories,  Ahmedabad  (INDIA).Ezetimibe  were 
obtained from MSN laboratories, Hyderabad (INDIA).  
Chromatographic  Conditions:  A  chromatographic  system 
UPLC  consisting  of  waters  acquity  system  equipped  with 
binary  solvent  delivery  pump an auto  sampler and tunable 
PDA  detector,  water  acquity  BEH  50*2.1mm,1.7um,  C18. 
The  instrumental  settings  were  a  flow  of  1ml/min.  The 
injection  volume  was  0.8ul.The  detection  wavelength  was 
248nm  for  all  three  analytes.The  peak  purity  was  checked 
with the photodiode array detector.  
Mobile  Phase:  The  mobile  phase  consisted  of  water  and 
acetonitrile in the ratio of 60:40(v/v). the pH of the mobile 
phase was adjusted to 6.5ml of orthophosphoric acid in the 
double  distilled  water.  The  mobile  phase  was  mixed  and 
filtered through a nylon filter and degassed
8-22. 
Preparation of Standard Solution 
10 mg of Atorvastatin was taken in a 10 ml standard flask. To 
this  2  ml  of  methanol  was  added  for  dissolving  the  drug. 
Sonicate it for one min. To get a clear solution and make up 
the volume to 10 ml with mobile phase (Stock solution A). 
10 mg of Ezetimibe was taken in a 10 ml standard flask and 
diluted  with  few  ml  of  mobile  phase  until  the  sample 
dissolves completely and make up the volume to 10 ml with 
mobile phase (Stock solution B). 
The internal standard solution was prepared by taking 10 mg 
of pioglitazone in a 10 ml standard flask. It is dissolved by 
adding 3 ml of a mixture of 0.1 % Orthophosphoric acid and 
Acetonitrile in the ration of 1:1. Sonicate for few minutes to 
get a clear solution and make up the final volume to 10 ml 
with mobile phase. 
The final standard solution was prepared in such a way that 
each  standard  flask  contains  1.5,  3,  4.5,  6  and  7.5  mg  of 
Atorvastatin and Ezetimibe and 5mg of pioglitazone (IS). 
Preparation of Formulation Solutions 
Twenty  tablets  each  containing  10  mg  of  Atorvastatin  and 
Ezetimibe  were  weighed  and  finely  powdered.  From  the Sharma Amit Kumar et al. IRJP 2012, 3 (3) 
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powdered tablet, a quantity of powder equivalent to 10 mg 
was weighed. This was then extracted with 25 ml each of 25 
ml of mixture of Acetonitrile and water (1:1 v/v). This was 
then  filtered  and diluted  to  100  mg/ml  of  Atorvastatin  and 
Ezetimibe. From this, 0.45 ml of Atorvastatin and Ezetimibe 
were drawn and mixed with 0.5 ml of internal standard so 
that these solutions when diluted to 10 ml with mobile phase 
contains  4.5  mg/ml  of  Atorvastatin  and  Ezetimibe  and  5 
mg/ml of internal standard (Table-1). 
Method or Recording of chromatogram 
With  the  optimized  chromatographic  conditions  mentioned 
above,  a  steady  baseline  for  about  20  min.  was  recorded. 
After the stabilization of the baseline for about 30 min., the 
standard  solution  were  injected  and  chromatograms  were 
recorded  until  the  reproducibility  of  the  peak  areas  was 
satisfactory and finally 0.8 ml of the standard solution of the 
individual  samples  were  injected  and  the  chromatograms 
were  recorded.  The  typical  chromatograms  of  the  sample 
solutions were also recorded and shown in Fig. 3. Successive 
aliquots of 0.8ml of mixed standard solutions were injected 
and the chromatograms were recorded. 
This procedure was repeated using the sample solution. The 
peak  areas  were  noted  and  the  response  factors  of  the 
standard  and  sample  solution  peaks  were  calculated.  The 
elution order of mixture was found as Atorvastatin (retention 
time 3.42), Pioglitazone (retention time 4.27) and Ezetimibe 
(retention time 6.89).  
Calibration curve solutions: The calibration curve solution 
containing  1.5,3,4.5,6  and7.5  ug/ml  of  Atorvastatin  and 
Ezetimibe  and  5ug/ml  of  pioglitazone  in  each  calibration 
level was prepared. 
RESULTS AND DISCUSSION 
Optimization of the chromatographic conditions 
Our objective of chromatographic method development was 
reducing analysis time,maintaining good efficiency, retention 
time  below  8  minutes,  Along  with  resolution  between 
Atorvastatin,Ezetimibe and internal standard (Pioglitazone). 
The  chromatographic  separation  was  achieved  using  water 
acquity  BEH  50*2  .1mm,  1.7um,  C18column.  The 
chromatographic  method  was  optimized  by  changing  the 
composition of mobile phase and pH of the mobile phase. 
Validation of the method: 
The  accuracy  of  the  method  was  determined  by  recovery 
experiments. The recovery studies were carried out 6 times 
and the percentage recovery and percentage relative standard 
deviation  of  the  percentage  recovery  were  calculated  and 
presented in Table 2. 
The  precision  of  the  method  was  determined  by  studying 
repeatability and reproducibility. The response factor of drug 
peaks  and  percentage  relative  standard  deviation  were 
calculated and presented in Table 3&4. The results revealed 
that the method developed is reproducible. 
The  standard  drug  solutions  in  varying  concentrations 
ranging from 50 to 150 % of the targeted level of the assay 
concentration containing internal standard were examined by 
the  assay  procedure.  The  linearity  and  range  for  both  the 
drugs was found to be from 1.5 to 7.5 mg/ml.  
The  response  factor,  slope,  intercept  and  correlation 
coefficient values were calculated. The correlation coefficient 
of Atorvastatin and Ezetimibe were found to be 0.996 and 
0.999 respectively. The calibration curves were plotted using 
response  factor  Vs  concentration  of  the  standard  solutions 
(Fig 5&6). The calibration graph shows that linear response 
was  obtained  over  the  range  of  concentrations  used  in  the 
assay procedure. These data demonstrates that the methods 
have adequate sensitivity to the concentration of the analytes. 
The range demonstrates that the method is linear outside the 
limits of expected use. 
The  LOD  and  LOQ  of  the  developed  method  were 
determined by analyzing progressively low concentration of 
the  standard  solutions  using  the  developed  methods.  The 
LOD is the smallest concentration of the analyte that gives a 
measurable response (signal to noise ratio     of 3). LOD of 
Atorvastatin, Ezetimibe  and  Pioglitazone  were  found to  be 
20, 20 and 50 ng/ml. the LOQ is the smallest concentration of 
the  analyte,  which  gives  response  that  can  be  accurately 
quantified  (signal  to  noise  ratio  of  10).  The  LOQ  of 
Atorvastatin, Ezetimibe  and  Pioglitazone  were  found to  be 
100, 100 and 500 ng/ml. 
The resolution, capacity factor, theoretical plates/meter, peak 
symmetry  was  calculated  for  the  standard  solutions and  is 
presented in Table 5& 6. The values obtained demonstrated 
the suitability of the system for the analysis of the above drug 
combination. 
SUMMARY AND CONCLUSION  
The  developed  UPLC  method  for  the  determination  of 
atorvastatin and ezetimibe was found to be capable of giving 
faster  retention  time  maintaining  good  resolution.  The 
method was completely validated showing satisfactory data 
for  all  the  parameters  used.  This  method  exhibited  an 
excellent  performance  in  terms  of  sensitivity  amnd  speed 
hence  can  be  used  for  routine  analysis  of  commercially 
available drugs.  
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Table 1: Analysis of Formulation 
Drug  Label Claim 
(mg/tablet) 
Estimated 
Amount 
(mg/tablet) 
% 
Label 
claim 
SD 
Atorvastatin  10  9.86  98.6  0.05 
Ezetimibe  10  10.16  101.6  0.01 
 
Table 2: Accuracy (Recovery Studies) 
S. 
No 
Name of 
the Drug 
Label 
Claim 
(mg/tablet) 
Amount 
added 
100% 
Amount 
recovered 
100% 
% 
Recovery 
RSD 
1.  Atorvastatin  10mg  10  9.28  92.8  0.013 
2.  Ezetimibe  10mg  10  9.87  98.7  0.011 
 
Table 3: Intra day Studies 
Rf of Atorvastatin  Mean  SD  RSD  Rf of 
Ezetimibe 
Mean  SD  RSD 
1.027 
1.023 
1.013 
1.042 
1.034 
1.027  0.0106  1.061 
1.402 
1.401 
1391 
1.403 
1.406 
1.4000  0.00568  0.405 
 
Table 4: Interday Studies 
Day  Rf of Atorvastatin  Mean  SD  RSD  Rf of Ezetimibe  Mean  SD  RSD 
Day 1 
1.023 
1.016 
1.036 
1.053 
1.011 
1.0278  0.015  1.47 
1.392 
1.413 
1.405 
1.401 
1.399 
1.402  0.0077  0.549 
Day 2 
1.021 
1.022 
1.034 
1.018 
1.012 
1.027  0.010  0.991 
1.406 
1.421 
1.403 
1.386 
1.412 
1.403  0.0105  0.748 
Day 3 
1.036 
1.028 
1.043 
1.018 
1.009 
1.0268  0.013  1.32 
1.412 
1.403 
1.394 
1.408 
1.401 
1.403  0.0068  0.484 
 
Table 5: Linearity and Range in HPLC 
Internal 
Standard 
Peak area 
(5m m m mg/ml) 
Atorvastatin  Ezetimibe 
Concentration 
(m m m mg/ml) 
Peak 
area 
Response 
factor 
Concentration 
(m m m mg/ml) 
Peak 
area 
Response 
factor 
490905 
490118 
525537 
515926 
514355 
1.5 
3 
4.5 
6 
7.5 
504733 
1031468 
1566001 
2083000 
2575820 
1.028 
2.104 
2.97 
4.037 
5.007 
1.5 
3 
4.5 
6 
7.5 
687828 
1017319 
1445075 
1748045 
2068693 
1.40 
2.07 
2.75 
3.38 
4.02 
 
Table 6: System suitability studies in HPLC 
Parameters  Atorvastatin  Ezetimibe  Pioglitazone 
Theoretical plates / meter  12126  22692  19234 
Resolution  3.32  3.41 
Capacity factor  0.2750  0.557  1.56 
LOD (mg /ml)  0.02  0.02  0.05 
LOQ (mg /ml)  0.06  0.06  0.15 
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Fig-2 Chromatogram of Recovery Studies  
 
 
 
 
 
Fig-3 Chromatogram of sample solution of Atorvastatin and Ezetimibe 
 
 
Fig-4 Overlain spectra of Atorvastatin and Amlodipine 
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Fig-5 Calibration curve of Atorvastatin  
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Fig-6 Calibration curve of Ezetimibe  
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